Technology Bundle ID: TAB-2023

Biological/Research Material for HIV Vaccine Research

Request More Info
Licensing Contact:
Primary Inventors: 
Bernard Moss (NIAID)
Co-Inventors: 
Linda Wyatt (NIAID)
Therapeutic Area: 
Infectious Disease
Development Status: 

Fully developed. Material has been used extensively in research.

Institute or Center: 
NIAID

Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines.

Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated vaccinia MVA virus to make recombinant MVA virus. The resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses the SIV 239gagpol gene and thus can be used to conduct vaccine studies in animal models such as Rhesus macaques.

The list of publications shown below demonstrates the usefulness of this biological material in HIV vaccine research.

Applications:
  • Research reagents useful in research and development in the area of HIV/AIDS vaccines.
Advantages:

CB Process - Initiated CB Process. Forwarded email to LPM. Requesting details concerning the new technology.

Patents

EIR Application

Research Material - Patent protection is not being pursued for this technology.

Publications

Amara RR, et al.
PMID 11393868
Amara RR, et al.
PMID 12021347
Amara RR, et al.
PMID 12097576
Earl PL, et al.
PMID 12009868
Sadagopal S, et al.
PMID 15731219

Updated

Oct 12, 2009

Data Source: 
tts